Plain-English translation of NCT06875245 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Wet age-related macular degeneration is a serious eye condition that damages your central vision. This study is testing a newer medication called faricimab, which works by blocking two different pathways involved in this disease. The trial will compare whether spacing out your injections every 8 weeks works just as well as spacing them every 12 weeks, after you receive an initial series of 4 monthly injections.
Current treatments for wet macular degeneration require frequent injections into the eye, which can be burdensome for patients. Doctors want to know whether this new medication allows for longer time between treatments without sacrificing your vision outcomes.
You likely qualify if…
You likely don't qualify if…
You will start with a screening visit and then receive 4 monthly injections into your eye. After that, you'll be randomly assigned to receive follow-up injections either every 8 weeks or every 12 weeks. You'll have regular eye exams and imaging scans (OCT) to check how well the treatment is working and measure your vision. The study will last roughly one year, with visits spreading out over time as your doctor adjusts the treatment intervals based on how your eye responds.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Czechia